Glenmark Pharmaceuticals on Thursday said it has become the first company in India to receive approval from Drug Controller General of India (DCGI) to conduct clinical trials of Favipiravir antiviral tablets for the treatment of COVID19 patients.

Having internally developed the active pharmaceutical ingredients (API) and the formulations for the product, the company filed the product for clinical trials with the DCGI and has received approval for conducting the trial on mild to moderate patients, Glenmark Pharmaceuticals said. The Mumbai-based company is the first pharmaceutical company in India to be given an approval by the regulator to start the trial on COVID-19 patients in the country, it added.

 Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections, it added.

Glenmark gets US approval for cancer drug, stock rise

Glenmark secures a position in Dow Jones SEM Index for 3-consecutive year

Jio may roll out 5G in H2 of 2021